544 related articles for article (PubMed ID: 34174986)
1. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
2. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
[TBL] [Abstract][Full Text] [Related]
4. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for anti-CD20 antibodies in CLL?
Shah HR; Stephens DM
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
[TBL] [Abstract][Full Text] [Related]
6. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
8. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
9. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
10. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Egyed M; Lueff S; Borbely J; Illes A
Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
[TBL] [Abstract][Full Text] [Related]
11. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Patel VK; Lamothe B; Ayres ML; Gay J; Cheung JP; Balakrishnan K; Ivan C; Morse J; Nelson M; Keating MJ; Wierda WG; Marszalek JR; Gandhi V
Leukemia; 2018 Apr; 32(4):920-930. PubMed ID: 29099493
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Mato AR; Roeker LE; Jacobs R; Hill BT; Lamanna N; Brander D; Shadman M; Ujjani CS; Yazdy MS; Perini GF; Pinilla-Ibarz JA; Barrientos J; Skarbnik AP; Torka P; Pu JJ; Pagel JM; Gohil S; Fakhri B; Choi M; Coombs CC; Rhodes J; Barr PM; Portell CA; Parry H; Garcia CA; Whitaker KJ; Winter AM; Sitlinger A; Khajavian S; Grajales-Cruz AF; Isaac KM; Shah P; Akhtar OS; Pocock R; Lam K; Voorhees TJ; Schuster SJ; Rodgers TD; Fox CP; Martinez-Calle N; Munir T; Bhavsar EB; Bailey N; Lee JC; Weissbrot HB; Nabhan C; Goodfriend JM; King AC; Zelenetz AD; Dorsey C; Bigelow K; Cheson BD; Allan JN; Eyre TA
Clin Cancer Res; 2020 Jul; 26(14):3589-3596. PubMed ID: 32198151
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
16. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Österborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
18. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
19. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
[TBL] [Abstract][Full Text] [Related]
20. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
